Vijaypd Ceutical Limited
Minimum investment
Bidding date
29 Sep - 01 Oct 2025
Price range
₹35 - ₹35
Minimum quantity
8,000
Minimum investment
₹1,40,000
Issue size
₹19.25 Cr.
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Category | Subscription |
|---|---|
Qualified Institutional Buyers | - |
Retail Individual Investor | - |
Non-Institutional Investor | - |
Others | - |
Total | - |
Incorporated in October 1971, Vijaypd Ceutical Ltd. is engaged in the distribution of pharmaceutical products and consumer goods. The company offers a wide range of services as representatives, dealers, agents, stockists, suppliers, traders, and packers.
The company caters to the pharmaceutical, wellness, and FMCG industries with a diverse product portfolio including medicines (injections, tablets, capsules, ointments, ophthalmic preparations, liquid orals), vitamins, hormones, enzymes, diagnostic kits, ayurvedic products, cosmetics, baby care, personal care, dental products, and food items.
As of March 31, 2025, the company serves over 2,109 pharmacies, clinics, and nursing homes across four districts in 20 locations. Its distribution network connects with more than 170 healthcare product manufacturers and provides access to over 19,000 SKUs. Vijaypd Ceutical is certified by FDA, FSSAI, and BMC, ensuring quality and reliability in its pharmaceutical supply chain.
Strong Client Relationships: The company has built long-term relationships with its clients, which helps strengthen its market presence and ensures recurring business opportunities.
Diversified Product Portfolio: Vijaypd Ceutical offers a wide range of pharmaceutical and FMCG products, catering to various healthcare and consumer needs under one platform.
Efficient Supply Chain Management: The company’s streamlined distribution network and supply chain enable it to serve thousands of pharmacies and clinics with reliable product availability.
Experienced Management Team: The leadership team has proven execution capabilities, backed by years of experience in pharmaceutical distribution and business growth.
Robust Financial Growth: The company has demonstrated strong revenue and profit growth in recent years, reflecting operational efficiency and growing market demand.
Dependence on Third-Party Manufacturers: The company relies heavily on external manufacturers for its product supply, which may affect business continuity if disruptions occur.
Highly Competitive Market: The pharmaceutical distribution industry is fragmented and competitive, which may impact pricing power and profitability.
Regulatory Challenges: The business operates in a sector that is strictly regulated by government authorities. Any changes in compliance requirements may affect operations.
Equity Dilution Post IPO: Promoter shareholding will fall from 78.30% to 56.25% after the IPO, indicating dilution of ownership.
High Minimum Investment Requirement: The IPO requires a minimum investment of Rs. 2.8 lakh for retail investors, which may reduce participation from small investors.
N/A
N/A
N/A
Active IPOs | |
|---|---|
Company name | Bid starts |
Cmr Green Technologies | 03-06-2026 |
Hexagon Nutrition | 05-06-2026 |
